Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Balancing Oncologic Outcomes With Patient Priorities in Prostate Cancer Care
4+ hour, 4+ min ago (50+ words) "I can’t make [treatment] decisions for you, but I can give you realistic expectations," said Herbert Lepor, MD, of NYU Langone Health. Aditya Bardia, MD, MPH, FASCO; Bachar Samra, MD Sara A. Hurvitz, MD, FACP; Shaina Rozell, MD, MPH Kamel…...
Breast Surgeon Reflects on Technology Reliance After Biopsy Needle Recall
6+ hour, 2+ min ago (54+ words) Kathryn Eckert, DO, spoke about diversifying breast imaging technology after the Hologic Brevera needle recall. CancerNetwork: How should situations like a shortage be mitigated in the future? Aditya Bardia, MD, MPH, FASCO; Bachar Samra, MD Sara A. Hurvitz, MD, FACP; Shaina…...
Mapping the Full CAR T-Cell Journey in DLBCL From Referral to Survivorship
11+ hour, 27+ min ago (308+ words) A multidisciplinary panel discussed second-line CAR T-cell candidacy, real-world referral barriers, and the management of delayed toxicities in DLBCL. Regarding when they refer patients for CAR T-cell evaluation, the panel was largely unanimous: at first relapse. George estimated that more…...
RASolute 302 and the Future of Pancreatic Cancer Treatment: Paul Oberstein, MD, on the KRAS Breakthrough
22+ hour, 21+ min ago (94+ words) Paul Oberstein, MD, discusses how RASolute 302 may be the most significant advance in pancreatic cancer treatment in more than a decade. The Moonlight Shift is available on YouTube and across MJH Life Sciences’ oncology platforms. New episodes, released bi-weekly, feature…...
Optimizing Surveillance Protocols After Focal Therapy for Prostate Cancer
1+ day, 2+ hour ago (53+ words) Herbert Lepor, MD, outlines NYU Langone’s long-term PSA and MRI surveillance protocol following focal cryoablation for prostate cancer. Aditya Bardia, MD, MPH, FASCO; Bachar Samra, MD Sara A. Hurvitz, MD, FACP; Shaina Rozell, MD, MPH Kamel Abou Hussein, MD 1 Sessions…...
Defining New Thresholds for Precisely Mitigating CAR T Toxicity
1+ day, 4+ hour ago (163+ words) Differentiating between CRS and IEC-HS remains a challenge in mitigating toxicity associated with cellular therapy, said Tiba Al Sagheer, PharmD, BCOP, BCACP. At the 2026 National ICE-T Conference in Orlando, sessions included a presentation titled “Thresholds and Therapeutics: A Precision Approach…...
Novel Agent Begins STARLIGHT-1 Dose Expansion in Relapsed/Refractory B-Cell NHL
1+ day, 8+ hour ago (473+ words) Among evaluable patients with B-cell NHL from the dose-escalation portion of the trial without CNS involvement, all CRs were sustained through 6 months. The first patient has been dosed in the dose-expansion phase of the phase 1/2 STARLIGHT-1 trial (NCT06343311) evaluating EB103, a CD19-redirected…...
Consolidative Radiotherapy Adds Toxicity Without Survival Benefit in SCLC
1+ day, 8+ hour ago (264+ words) Based on phase 2 data, adding consolidative thoracic radiation cannot be recommended outside of clinical trials for unselected patients with ES-SCLC. Adding consolidative thoracic radiotherapy (TRT) to atezolizumab (Tecentriq) maintenance increased severe and fatal toxicity without improving survival in patients with…...
How to Speak With Patients About Potential Changes to Care During Biopsy Needle Delays
1+ day, 9+ hour ago (96+ words) Kathryn Eckert, DO, shared how her team communicates with patients and keeps referral guidelines unchanged during the shortage. CancerNetwork: If you are dealing with specific delays, how do you manage that conversation with the patient? CancerNetwork: Looking at the referral…...
Seven-Year Data Drive Patient Preference for Focal Prostate Cancer Therapy
1+ day, 10+ hour ago (146+ words) When presented with validated long-term outcome data, most men with intermediate-risk prostate cancer favor a focal approach over radical intervention. In an interview with CancerNetwork®, Herbert Lepor, MD, highlighted how robust evidence shapes patient decision-making: Evolving Data: Patient uptake grew…...